Innate Pharma S.A.
NASDAQ:IPHABiotechnology
+$0.03 today
- Market cap
- $115.05M
- Beta
- 0.89
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.54
Volume 0.50M
Average 0.07M
Returns on capital
Innate Pharma S.A. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
226.7%
avg -54.9%
ROIC
-152.0%
avg -27.8%
ROA
-78.4%
avg -19.7%
Analysis
ROE is currently the strongest return metric at 226.7% versus its period average of -54.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jonathan E. Dickinson | Chief Executive Officer & Director | EUR 1.06M | 58 | — | — |
Sonia Quaratino | Executive Vice President & Chief Medical Officer | EUR 217.06K | 64 | — | — |
Yannis Morel | Executive Vice President & Chief Operating Officer | EUR 183.9K | 53 | — | — |
Marc Bonneville | Founder | — | 66 | — | — |
Alessandro Moretta | Founder | — | — | — | — |
Jean Jacques Fournié | Founder | — | — | — | — |
Frederic Lombard | Senior Vice President & Chief Financial Officer | — | 51 | — | — |
Claire de Saint Blanquat | Vice President of Legal & Corporate Affairs and Secretary of the Supervisory Board | — | 53 | — | — |
Odile Belzunce | VP, Chief of Compliance & Operations Officer and Interim Head of HR | — | 46 | — | — |
Stephanie Cornen | Vice President of Investor Relations, Communication & Commercial Strategy | — | 39 | — | — |
François Romagné | Founder | — | 62 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -63.6% | +120.9% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -63.6% over three years. Forward estimates point to Revenue at +120.9% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Innate Pharma S.A. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about IPHA's management, answered from reported figures.
Who manages IPHA?
Innate Pharma S.A. (IPHA) lists 11 active executives. The top listed executive is Marc Bonneville, Founder.
Continue the stock analysis
Jump to another research area for this company.